Table S1. Summary of the DERBY, OAKS, GATHER 1 and GATHER 2 Clinical Trials.

	DERBY			OAKS			GATHER 1		GATHER 2	
	Peg Monthly	Peg Every Other Month	Sham	Peg Monthly (N=202)	Peg Every Other Month (N=205)	Sham	ACP 2 mg N=67	Sham N=110	ACP 2 mg N=225	Sham N=222
Age (Years)	78.7	79.2	78.6	78.8	78.1	78.6	78.8	78.2	76.3	76.7
Female	118 (58.7%)	120 (59.7%)	123 (63.1%)	125 (61.9%)	117 (57.1%)	133 (64.3%)	45 (67.2%)	79 (71.8%)	154 (68.4%)	156 (70.3)
Baseline GA Mean Total Area (mm2)	8.37	8.25	8.24	8.18	8.30	8.21	7.33	7.42	7.48	7.81
Baseline Square Root GA Lesion Size (mm)	2.80	2.79	2.78	2.78	2.80	2.79	2.62	2.63	2.64	2.71
Baseline BCVA (Letters)	59.5	58.7	59	61	58.2	57.6	70.2	69	70.9	71.6
Reduction in GA Lesion Growth at Month 12 When Compared to Sham	12% p=0.0528	11% p=0.075		22% p=0.0003	16% p=0.0052		35.4% p=0.0050		17.7% p=0.0039	
CNV*	25 (6.0%)	17 (4.1%)	10 (2.4%)	DERBY	OAKS	COMBINED	6 (9%)	3 (2.7%)	15 (6.7%)	9 (4.1%)

	DERBY			OAKS			GATHER 1		GATHER 2	
Endophthalmitis*	1	2	0	DERBY	OAKS	COMBINED	0	0	0	0
IOI*	9 (2.1%)	4 (1%)	0	DERBY	OAKS	COMBINED	1 (1.5%)	0	0	0
ION	0	0	0	1 (0.5%)	0	0	0	0	0	0

Peg=pegcetacoplan; ACP=avacincaptad; CNV=choroidal neovascularization; IOI=intraocular inflammation; ION=ischemic optic neuropathy; * DERBY & OAKS combined